Late clinical and laboratory manifestations of thorotrast administration in cerebral arteriography. A follow-up study of thirty patients

Identification of thorotrast by gamma-spectrometry and simplified autoradiography in pathological specimens

Simplified and reliable methods for identifying thorotrast are demonstrated. On gamma-ray spectrometry, as little as 0.1 g of liver tissue gives gamma-ray spectrum characteristics to the thorium decay series, despite a low net count. When conventional film for photography is kept in contact with a paraffin section of the liver for 4 months, it develops silver grains exactly corresponding to the area of granular deposition. By combining this method with clinical and pathological findings, a diagnosis of thorotrastosis can be established without the need for special instruments or materials.

Spurious dual-energy X-ray absorptiometry images in a patient exposed to the contrast agent Thorotrast

A 69-year-old woman presented with a 20-year history of back pain and a 10 cm height loss. She had received an injection of the contrast agent, Thorotrast, at age 23. There was no history of fluoride exposure. Multiple vertebral compression fractures were seen on radiographs. Dual-energy X-ray absorptiometry (DXA) scans revealed high normal bone mineral content on the spine and, on whole body scan, visualization of the liver and spleen regions. Given the attenuation coefficient of thorium and the thorium concentrations reported for liver, spleen and vertebral bodies, it is likely that thorium was visualized in the liver and spleen and that it caused spurious elevation in her DXA bone mineral content values.

Haemangioendothelioma (Kupffer cell angiosarcoma), myelofibrosis, splenic atrophy, and myeloma paraproteinaemia after parenteral thorotrast administration

A case of thorotrastosis occurred 25 years after thorotrast angiography, with the previously unrecorded association of myeloma type paraproteinaemia. The relationship between haemangioendothelioma due to thorotrast and other vascular sarcomas of the liver is briefly reviewed.

Cervical Thorotrast granuloma: an iatrogenic cause of dysphagia

Thorotrast granuloma of the neck is an extensive benign connective tissue overgrowth secondary to localized extravasation of contrast. This can present with dysphagia secondary to mass effect or motor disorder of swallowing related to demyelinization of the ninth through twelfth cranial nerves. The radiographic appearance is characteristic in both location and density.

Fourteen-year remission of acute leukemia in a patient exposed to thorotrast

A case report of a patient who developed acute myelogenous leukemia 15 years after injection of Thorotrast and who has been in a sustained long term remission for 14 years is presented with a review of the problems associated with Thorotrast, subsequently shown to be radioactive with long term sequelae.

Cholagiocarcinoma in a patient previously given thorotrast

The long-term effects of thorotrast administration include local granulomas, blood cell abnormalities, and cancer. To date, more than 100 cases of liver cancer have been reported in patients previously given this radioactive contrast material, with a latency period of approximately 22 years. We report such a case; the patient not only had a thorotrast-induced cholangiocarcinoma, but also showed striking morphologic changes in the red blood cells secondary to splenic dysfunction.